This application seeks renewed CCSG funding for the University of Virginia (UVA) Cancer Center, a matrix cancer center that brings together 132 Members from 23 Departments in the Schools of Medicine, Nursing, and Engineering, and in the College of Arts and Sciences. The UVA Cancer Center receives $19.85M from NCI, $48.62M from other peer-reviewed sources, and $8.72M from non-peer-reviewed sources, for a total of $77.19M in overall funding. Through faculty recruitment, re-organization, and robust infrastructure development, the UVA Cancer Center has continued to build on its exceptional basic-science foundations and has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Twenty-six new faculties have been recruited, including thirteen clinical investigators and/or physician-scientists and eight bioengineers, computational biologists, and/or molecular geneticists. To enhance trans-disciplinary and translational research and cancer focus, programs were consolidated so that all have basic science Members integrated with disease-focused and clinical or translational investigators. The Cancer Center has five Programs;Cancer Cell Signaling (SIG), Chemical and Structural Biology (CSB), Molecular Genetics and Epigenetics (GEN), Women's Oncology (WON), and Immunology/immunotherapy (IMM). The number of Full Members has been reduced by 30% and an Associate Member category has been created for investigators whose potential for peer-reviewed, cancer-focused research has yet to be actualized. This application requests support for eight Shared Resources: Advanced Microscopy, Biomolecular Analysis, Biorepository and Tissue Research, Flow Cytometry, Gene Targeting and Transgenic, Preclinical Tumor Analysis and Imaging, Biostatistics, and the Office for Clinical Research. A completely transformed infrastructure for translational and clinical research facilitates investigations using human tissues and the implementation of clinical trials. Major additions in research and clinical facilities strongly enhance the Cancer Center's ability to carry out its mission: New laboratory space covering 25,000 ft2houses IMM and WON Members, and a new cancer outpatient clinical building covering 151,000 ft2 will open in April 2011. Substantial activities have been initiated to reach underserved populations in minority groups and in Appalachia. This renewal application describes continued excellence in basic cancer research, enhanced cancer focus, and greatly strengthened clinical research leadership and infrastructure.

Public Health Relevance

The UVA Cancer Center's dual mission is to eliminate the threat of cancer, with skilled, compassionate care for the patients of today and with research and education for the patients of the future. Cancer Center Members draw on the deep resources of the University of Virginia to identify, analyze, and validate some of the most significant targets for cancer therapy, diagnosis and prevention, and to speed their translation to clinical application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-22
Application #
8481518
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-16
Project End
2017-01-31
Budget Start
2013-03-12
Budget End
2014-01-31
Support Year
22
Fiscal Year
2013
Total Cost
$2,331,566
Indirect Cost
$855,892
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications